JP2005533751A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533751A5 JP2005533751A5 JP2003577859A JP2003577859A JP2005533751A5 JP 2005533751 A5 JP2005533751 A5 JP 2005533751A5 JP 2003577859 A JP2003577859 A JP 2003577859A JP 2003577859 A JP2003577859 A JP 2003577859A JP 2005533751 A5 JP2005533751 A5 JP 2005533751A5
- Authority
- JP
- Japan
- Prior art keywords
- donating
- drug delivery
- delivery composition
- solid drug
- porous particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 46
- 239000002245 particle Substances 0.000 claims description 41
- 238000012377 drug delivery Methods 0.000 claims description 35
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 34
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 34
- 239000004094 surface-active agent Substances 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 34
- 238000004519 manufacturing process Methods 0.000 claims 8
- 229960001259 diclofenac Drugs 0.000 claims 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 4
- 238000003756 stirring Methods 0.000 claims 4
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 3
- 229960000991 ketoprofen Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229960002009 naproxen Drugs 0.000 claims 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 3
- -1 polyoxyethylene Polymers 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 229920001400 block copolymer Polymers 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 claims 1
- CLFSHUKVMLTNAV-UHFFFAOYSA-N 3-nitrooxypropyl 2-(3-benzoylphenyl)propanoate Chemical compound [O-][N+](=O)OCCCOC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 CLFSHUKVMLTNAV-UHFFFAOYSA-N 0.000 claims 1
- CQVHWLHWUZRTQC-UHFFFAOYSA-N 4-nitrooxybutyl 2-[2-(2,6-dichloroanilino)phenyl]acetate Chemical compound [O-][N+](=O)OCCCCOC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl CQVHWLHWUZRTQC-UHFFFAOYSA-N 0.000 claims 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 1
- 229940121819 ATPase inhibitor Drugs 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- BLGCOWFCUDFELQ-UHFFFAOYSA-N [4-(nitrooxymethyl)phenyl]methyl 2-(3-benzoylphenyl)propanoate Chemical compound C=1C=CC(C(=O)C=2C=CC=CC=2)=CC=1C(C)C(=O)OCC1=CC=C(CO[N+]([O-])=O)C=C1 BLGCOWFCUDFELQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 229960004770 esomeprazole Drugs 0.000 claims 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 claims 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 1
- 229960003174 lansoprazole Drugs 0.000 claims 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims 1
- 229950007395 leminoprazole Drugs 0.000 claims 1
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 claims 1
- 229960000381 omeprazole Drugs 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229960004157 rabeprazole Drugs 0.000 claims 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 229920002023 Pluronic® F 87 Polymers 0.000 description 2
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 229920002511 Poloxamer 237 Polymers 0.000 description 1
- 229920002517 Poloxamer 338 Polymers 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000010436 fluorite Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200895A SE0200895D0 (sv) | 2002-03-22 | 2002-03-22 | New pharmaceutical composition |
| PCT/SE2003/000468 WO2003080029A1 (en) | 2002-03-22 | 2003-03-20 | No-donating nsaids adsorbed into carrier particles |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010171855A Division JP2010285445A (ja) | 2002-03-22 | 2010-07-30 | 担体粒子に吸着されたｎｏ−供与ｎｓａｉｄ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005533751A JP2005533751A (ja) | 2005-11-10 |
| JP2005533751A5 true JP2005533751A5 (enExample) | 2010-12-02 |
Family
ID=20287374
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003577859A Withdrawn JP2005533751A (ja) | 2002-03-22 | 2003-03-20 | 担体粒子に吸着されたｎｏ−供与ｎｓａｉｄ |
| JP2010171855A Abandoned JP2010285445A (ja) | 2002-03-22 | 2010-07-30 | 担体粒子に吸着されたｎｏ−供与ｎｓａｉｄ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010171855A Abandoned JP2010285445A (ja) | 2002-03-22 | 2010-07-30 | 担体粒子に吸着されたｎｏ−供与ｎｓａｉｄ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050129774A1 (enExample) |
| EP (1) | EP1490033A1 (enExample) |
| JP (2) | JP2005533751A (enExample) |
| AR (1) | AR038951A1 (enExample) |
| AU (1) | AU2003216006A1 (enExample) |
| SE (1) | SE0200895D0 (enExample) |
| TW (1) | TW200307564A (enExample) |
| UY (1) | UY27727A1 (enExample) |
| WO (1) | WO2003080029A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6852739B1 (en) | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
| IT1319202B1 (it) | 2000-10-12 | 2003-09-26 | Nicox Sa | Farmaci per le malattie a base infiammatoria. |
| ITMI20021392A1 (it) * | 2002-06-25 | 2003-12-29 | Nicox Sa | Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' |
| WO2004012659A2 (en) | 2002-08-01 | 2004-02-12 | Nitromed, Inc. | Nitrosated proton pump inhibitors, compositions and methods of use |
| ATE359075T1 (de) | 2002-12-20 | 2007-05-15 | Niconovum Ab | Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose |
| SE0301880D0 (sv) * | 2003-06-25 | 2003-06-25 | Astrazeneca Uk Ltd | New drug delivery composition |
| EP1682092A2 (en) * | 2003-11-13 | 2006-07-26 | Alza Corporation | Melt blend dispersions comprising a low water solubility drug and an ethylene oxide-propylene oxide block copolymer |
| AU2007224584A1 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
| WO2008101064A1 (en) * | 2007-02-14 | 2008-08-21 | Logical Therapeutics, Inc. | Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist |
| WO2009012425A2 (en) * | 2007-07-19 | 2009-01-22 | Logigal Therapeutics, Inc. | Compositions including leukotriene antagonists and nsaids and methods of using the same |
| WO2009149053A2 (en) * | 2008-06-02 | 2009-12-10 | Dr. Reddy's Laboratories Ltd. | Naproxcinod process and solid dispersion |
| US8833378B2 (en) * | 2008-09-17 | 2014-09-16 | Niconovum Ab | Process for preparing snuff composition |
| DE102010052847A1 (de) * | 2010-11-29 | 2012-05-31 | Temmler Werke Gmbh | Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung |
| EP3046545B1 (en) * | 2013-09-20 | 2020-02-26 | Tillotts Pharma AG | Delayed release pharmaceutical formulation |
| EP3222273B1 (en) | 2014-11-18 | 2019-09-25 | National Institute for Materials Science | Method for producing porous particle |
| GB201502077D0 (en) * | 2015-02-09 | 2015-03-25 | Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd | Improved hme technology |
| GB201502073D0 (en) * | 2015-02-09 | 2015-03-25 | Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd | HDEG technology |
| EP4514325A1 (en) * | 2022-04-29 | 2025-03-05 | MannKind Corporation | Method and composition for treating lung diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2700141B2 (ja) * | 1993-09-17 | 1998-01-19 | 富士化学工業株式会社 | リン酸水素カルシウム及びその製法並びにそれを用いた賦形剤 |
| JPH08301763A (ja) * | 1995-04-28 | 1996-11-19 | Dainippon Pharmaceut Co Ltd | 易溶性粉末状医薬組成物およびその製造方法 |
| IL143846A0 (en) * | 1998-12-23 | 2002-04-21 | Alza Corp | Dosage forms comprising porous particles |
| AU779277B2 (en) * | 1999-06-04 | 2005-01-13 | Alza Corporation | Implantable gel compositions and method of manufacture |
| US6793934B1 (en) * | 1999-12-08 | 2004-09-21 | Shire Laboratories, Inc. | Solid oral dosage form |
| JP2001316248A (ja) * | 2000-02-28 | 2001-11-13 | Eisai Co Ltd | 油状薬物含有組成物の製造方法 |
| SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| US7101573B2 (en) * | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
| ITMI20021392A1 (it) * | 2002-06-25 | 2003-12-29 | Nicox Sa | Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' |
-
2002
- 2002-03-22 SE SE0200895A patent/SE0200895D0/xx unknown
-
2003
- 2003-03-12 AR ARP030100860A patent/AR038951A1/es not_active Application Discontinuation
- 2003-03-20 TW TW092106166A patent/TW200307564A/zh unknown
- 2003-03-20 AU AU2003216006A patent/AU2003216006A1/en not_active Abandoned
- 2003-03-20 UY UY27727A patent/UY27727A1/es not_active Application Discontinuation
- 2003-03-20 WO PCT/SE2003/000468 patent/WO2003080029A1/en not_active Ceased
- 2003-03-20 JP JP2003577859A patent/JP2005533751A/ja not_active Withdrawn
- 2003-03-20 US US10/507,368 patent/US20050129774A1/en not_active Abandoned
- 2003-03-20 EP EP03745055A patent/EP1490033A1/en not_active Withdrawn
-
2010
- 2010-07-30 JP JP2010171855A patent/JP2010285445A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533751A5 (enExample) | ||
| RU2158138C2 (ru) | Фармацевтические лекарственные формы для перорального приема, содержащие ингибитор протонного насоса и средство нестероидной противовоспалительной терапии | |
| JP2010285445A (ja) | 担体粒子に吸着されたｎｏ−供与ｎｓａｉｄ | |
| JP4546643B2 (ja) | 酸不安定な活性化合物を含有する新規の坐剤形 | |
| EP1521574B1 (fr) | Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation | |
| JP5714492B2 (ja) | 粒状体、それらの調製方法、およびそれらを含む医薬品 | |
| ES2246238T3 (es) | Nueva preparacion y forma de administracion que comprende un inhibidor de las bombas de protones labil en medio acido. | |
| US20190254976A1 (en) | Medicament-containing hollow particle | |
| UA69396C2 (uk) | ПЕРОРАЛЬНА ДОЗОВАНА ФАРМАЦЕВТИЧНА ФОРМА З ДИСКРЕТНИМ ВИВІЛЬНЕННЯМ ІНГІБІТОРА Н<sup>+</sup>,К<sup>+</sup>,-АТФ-АЗИ (ВАРІАНТИ) ТА СПОСІБ ЇЇ ОДЕРЖАННЯ (ВАРІАНТИ) І СПОСІБ ЛІКУВАННЯ (ВАРІАНТИ) | |
| JPH09511767A (ja) | 新規な経口用の医薬使用形態 | |
| JP2005530835A (ja) | 改良された生物学的利用能を有する液体薬剤の経口医薬形態 | |
| JPH09511768A (ja) | 新規な製剤および方法 | |
| UA69397C2 (uk) | ПЕРОРАЛЬНА ДОЗОВАНА ФАРМАЦЕВТИЧНА ФОРМА ПОДОВЖЕНОЇ ДІЇ ІНГІБІТОРА Н<sup>+</sup>,К<sup>+</sup>,-АТФ-АЗИ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА СПОСІБ ЛІКУВАННЯ | |
| KR101907690B1 (ko) | 비스테로이드성 항염증약물 및 프로톤 펌프 저해제를 포함하는 약제학적 복합제제 및 이의 제조방법 | |
| WO2007103453A1 (en) | Ezetimibe compositions | |
| RU2007126652A (ru) | Композиции и способы стабилизации активных фармацевтических ингредиентов | |
| HU202102B (en) | Process for producing oral pharmaceutical compositions with controlled release of the active components | |
| JP2006528221A5 (enExample) | ||
| JP2004514733A (ja) | 酸分解性活性成分を含有するペースト形の医薬品製造物 | |
| CN1135981C (zh) | 硫酸吗啡微粒、其制备方法和药物制剂 | |
| JP3909998B2 (ja) | 経口投与製剤 | |
| JPWO2007074910A1 (ja) | 放出制御固形製剤 | |
| TW201211025A (en) | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists | |
| JP6160263B2 (ja) | ロキソプロフェン含有医薬組成物 | |
| CA2449352A1 (en) | Nsaid formulation comprising a granular composition and an extra-granular composition |